Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03598790 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,353
- Enrollment target
NCT03598790: Completed Phase 3 study, sponsored by UCB Biopharma SRL.
NCT03598790 is a Phase 3 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 1,353 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03598790, a Phase 3 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,353 participants
- Enrollment target
Study Summary
This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
Primary Outcome
The number of TEAEs adjusted by duration of exposure to study treatment were scaled such that it provides an incidence rate per 100 patient-years. If a participant had multiple events, the time of exposure was calculated to first occurrence of the AE being considered. If a participant had no events, the total time at risk was used.
Interventions
- DRUG Bimekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,353 participants |
| Start Date | 2018-09-05 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 3 |
What the finished NCT03598790 record still lists
NCT03598790 is an interventional study that assigns participants to a tested intervention. Its 1,353 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% higher).
The record links to 0 conditions, and to 1 intervention - of which Bimekizumab is the first listed.
NCT03598790 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03598790 about?
NCT03598790 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis". This is a study to evaluate the long-term safety and tolerability of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis (PSO).
What is the current status of trial NCT03598790?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,353 participants. The study started on 2018-09-05. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT03598790?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT03598790?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03598790's enrollment target sits among peer trials
1,353 181st of 2000 higher than 1,820 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06318169 · 1,350 participants · Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- NCT06605404 · 1,350 participants
Pan-tumor MRD Study
- NCT06806163 · 1,350 participants · NA
Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
- NCT05245227 · 1,358 participants · Phase 3
Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI